Navigation Links
Halozyme Announces Positive Results from Roche's Subcutaneous Herceptin Phase 3 Trial
Date:10/17/2011

orical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning the timing, scope and outcomes of our clinical trials as well as expected activities under our collaborative partnerships) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including clinical trial enrollment and results, regulatory approval requirements and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the company's reports on Forms 10-K, 10-Q, and other filings with the Securities and Exchange Commission.

Halozyme Contact
Kurt Gustafson
Chief Financial Officer
(858) 704-8272
kgustafson@halozyme.com


'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer
2. Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
3. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
4. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
5. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
6. Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
7. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
8. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
9. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
10. Halozyme Provides HYLENEX® Product Reintroduction Update
11. Halozyme Therapeutics Announces Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... 27, 2015  A mere one in seven new ... Hamilton . A new white paper from ... impeding and disrupting manufacturers, success. The white ... Value In Product Development Processes provides insight into: ... how it affects the product development process resulting in: ...
(Date:8/27/2015)... Aug. 27, 2015 NorthStar Anesthesia , one ... it has been selected by Mercy, based in ... four of their hospitals:  Mercy St. Vincent  Medical Center and ... , Mercy St. Charles  Hospital in Oregon ... Tiffin . "As we looked to ...
(Date:8/27/2015)... , August 27, 2015 According ... Market by Type (Integrated, Standalone), by Deployment Mode (Web ... Physicians, Emergency Healthcare Service Providers), by Component - Global ... Systems Market is estimated at $501.1 Million 2014, and ... a CAGR of 7.6% from 2014 to 2019. ...
Breaking Medicine Technology:New White Paper Reveals How Manufacturers Can Improve Product Development Processes 2Four Mercy Hospitals in Northwest Ohio Select NorthStar Anesthesia 2Radiology Information Systems Market Worth $722.7 Million by 2019 2Radiology Information Systems Market Worth $722.7 Million by 2019 3Radiology Information Systems Market Worth $722.7 Million by 2019 4
(Date:8/28/2015)... Raleigh, NC (PRWEB) , ... August 28, 2015 , ... ... mesothelioma will not be available for general use any time soon, according to educational ... MTG-201, a biologic therapy that received orphan drug designation for mesothelioma last week from ...
(Date:8/28/2015)... , ... August 28, 2015 , ... External Counterpulsation, also ... Fit Clinic is now selling External Counterpulsation (EECP or ECP) machines with a full ... Clinic has been in business since 2007 helping people prevent and reverse heart ...
(Date:8/28/2015)... ... August 28, 2015 , ... Inc. magazine today ranked ... exclusive ranking of the nation’s fastest-growing private companies. The list was unveiled online at ... of 85% over the last three years, PREVENT ranks higher on the list than ...
(Date:8/28/2015)... , ... August 28, 2015 , ... Santa Rosa was ... Work in Healthcare by Modern Healthcare. In the KLAS “2015 Midterm Performance Review: Software ... , “We believe the recognitions from Modern Healthcare and KLAS are directly related to ...
(Date:8/27/2015)... ... August 28, 2015 , ... Best-selling ... of foster care through “The Language of Flowers,” has joined the Youth Villages ... particularly the organization’s YVLifeSet program, was piqued by her passion for helping foster ...
Breaking Medicine News(10 mins):Health News:Surviving Mesothelioma Puts New Orphan Drug into Perspective in New Article 2Health News:Buy New External Counterpulsation (EECP or ECP) With Heart Fit Clinic 2Health News:PREVENT Life Safety Ranks No. 3660 on the 2015 Inc. 5000 With Three-Year Sales Growth of 85% 2Health News:Santa Rosa Consulting Recognized by Modern Healthcare as One of the Top 100 Best Places to Work and from KLAS Research with the Highest Rating for Go-Live Support 2Health News:Best-selling Author Vanessa Diffenbaugh Joins Youth Villages National Board of Directors 2Health News:Best-selling Author Vanessa Diffenbaugh Joins Youth Villages National Board of Directors 3
... a leading,international manufacturer, marketer, and supplier of protective ... 2007 fourth,quarter and full year financial results., ... generated net sales of,$253.7 million, an increase of ... fourth quarter of 2006. Excluding the impact of ...
... therapy has an impact on overall day-to-day living, experts ... issues should be weighed carefully when prostate cancer patients ... them, new research suggests. , Different therapies can ... living, and these outcomes need to be discussed with ...
... WASHINGTON, March 19 Health and Human,Services Secretary ... by Deirdre McQuade, spokesperson on pro-life issues for,the ... comments on March 19,following a public attack on ... The attack was prompted by a March ...
... and other chemicals in childhood may hike adult cancer risks, ... In the decades following World War II, both breast cancer ... United States -- and a new report contends there,s a ... Breast Cancer Fund, a non-profit group whose mission is to ...
... International Associates Inc.,administrator for the HealthShares(TM) Indexes, a series ... announced the,quarterly rebalancing of the Indexes., The following ... before the opening of trading on NYSE Arca March ... GW Pharmaceuticals, Inc (LSE: GWP.L) ...
... March 19 Integrated,Pharmaceutical, Inc. (OTC Bulletin ... orders for its new no calorie, electrolyte ... and Magnesium, called,HEALTHYCAL+. The first bottles are ... Sales representatives report more than 40 ...
Cached Medicine News:Health News:Pregis Announces Fouth Quarter and Full Year 2007 Financial Results 2Health News:Pregis Announces Fouth Quarter and Full Year 2007 Financial Results 3Health News:Pregis Announces Fouth Quarter and Full Year 2007 Financial Results 4Health News:Pregis Announces Fouth Quarter and Full Year 2007 Financial Results 5Health News:Pregis Announces Fouth Quarter and Full Year 2007 Financial Results 6Health News:Pregis Announces Fouth Quarter and Full Year 2007 Financial Results 7Health News:Pregis Announces Fouth Quarter and Full Year 2007 Financial Results 8Health News:Pregis Announces Fouth Quarter and Full Year 2007 Financial Results 9Health News:Pregis Announces Fouth Quarter and Full Year 2007 Financial Results 10Health News:Pregis Announces Fouth Quarter and Full Year 2007 Financial Results 11Health News:Quality of Life an Issue in Prostate Cancer Treatment 2Health News:Quality of Life an Issue in Prostate Cancer Treatment 3Health News:HHS Secretary Leavitt Praised for Defending Physicians' Conscience Rights 2Health News:Environmental Toxins, Radiation May Be Tied to Breast Cancer 2Health News:Environmental Toxins, Radiation May Be Tied to Breast Cancer 3Health News:Environmental Toxins, Radiation May Be Tied to Breast Cancer 4Health News:QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes 2Health News:QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes 3Health News:QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes 4Health News:QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes 5Health News:QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes 6Health News:QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes 7Health News:QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes 8Health News:QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes 9Health News:QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes 10Health News:QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes 11Health News:QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes 12Health News:QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes 13Health News:QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes 14Health News:QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes 15Health News:Retailers Sign on to Sell the New HEALTHYCAL+ Water Beverage - Even Before First Bottle is Packaged 2Health News:Retailers Sign on to Sell the New HEALTHYCAL+ Water Beverage - Even Before First Bottle is Packaged 3
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 19.0 mm and length 21 mm....
... The BacT/Alert 3D Select ... art, automated microbial detection system ... fluid and mycobacteria culturing. This ... data management or laboratory information ...
IDS Rapid ANA II System, a microbial identification system....
IDS Rapid One, a microbial identification system....
Medicine Products: